Silk Road Medical (SILK)
(Delayed Data from NSDQ)
$27.09 USD
+0.03 (0.11%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $27.08 -0.01 (-0.04%) 4:22 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.09 USD
+0.03 (0.11%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $27.08 -0.01 (-0.04%) 4:22 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
All You Need to Know About Silk Road Medical (SILK) Rating Upgrade to Buy
by Zacks Equity Research
Silk Road Medical (SILK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
Silk Road Medical (SILK) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 17.50% and 11.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 13.58% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 10.26% and 4.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?
by Zacks Equity Research
RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Silk Road Medical (SILK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.26% and 1.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.11% and 15.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 21.95% and 12.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 200% and 6.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 8.11% and 7.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 3.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Silk Road Medical (SILK) a New Strong Buy Stock
by Zacks Equity Research
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?